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base. Int Arch Occup Environ Health 2011;84:889–897.Controlling gastric variceal bleeding with endoscopically applied
hemostatic powder (HemosprayTM)To the Editor:
Gastric variceal bleeding tends to be more severe (2.9 vs. 4.8
transfusion units per patient) and is associated with a higher mor-
tality (30% vs. 45%) than bleeding from oesophageal varices [1–3].
Failure of endoscopic therapy commonly requires rescue
placement of a transjugular intrahepatic portosystemic shunt
(TIPS) [4], but this option is costly and not always feasible.
HemosprayTM is a novel hemostatic spray recently introduced
for the management of non-variceal upper gastrointestinal bleed-
ing [5].
We describe the ﬁrst case of variceal bleeding refractory to
standard endoscopic therapy, successfully treated with Hemo-
sprayTM, obviating the need for TIPS.
A 79-year-old woman presented to the emergency department
with a 3-day history of melena. Her previous medical history
included idiopathic myeloﬁbrosis with hepatosplenomegaly due
to extramedullary hematopoiesis. This was complicated by portal
hypertension and ascites. Furthermore, she suffered from a severe
hypertension-related pre-existent dilated cardiomyopathy. Previ-
ous upper endoscopy did not show the presence of varices.
At presentation she had a blood pressure of 80/40 mmHg with
a pulse rate of 90 bpm with peripheral cyanosis. On rectal exam-
ination, black stools were noticed. Laboratory test results showed
haemoglobin 4.8 mmol/L, urea 27 mmol/L, creatinine 68 mmol/L,
INR 1.4, and normal transaminases and bilirubin.
In anticipation of a variceal haemorrhage, standard adminis-
tration of an antibiotic (norﬂoxacin 400 mg twice daily) and vaso-
pressor drugs (octreotide) was initiated. Fluid and packed cell
administration was restricted to stabilize vital signs. The patient
was meanwhile transferred to the intensive care unit.
Upper gastrointestinal endoscopy was performed using an
Olympus Q180-1T scope (Olympus, Japan). In the distal esopha-
gus, small varices without bleeding stigmata were seen, but in
the gastric fundus, a profusely bleeding varix of 8 mm (GOV2
[2]) was observed. Next, in three consecutive injections, a total
volume of 2.6 ml HistoAcrylTM with lipiodol was injected. How-
ever, hemostasis could not be achieved and hemodynamic insta-
bility ensued. Rescue treatment with TIPS was considered, but
not pursued given her cardiac condition. Instead of injecting
more HistoAcrylTM, we decided to apply HemosprayTM (Cook
Medical, USA). For this, we sprayed approximately 10 g of
HemosprayTM covering the entire bleeding varix. Persistent
hemostasis was conﬁrmed after 5 min of visual inspection.
The patient received standard post-endoscopic care and went
home. No rebleeding occurred at follow-up at day 7 and 30. We
did not perform a second-look endoscopy given the absence of
signs of rebleeding.
Gastric variceal haemorrhage is an acute life-threatening con-
dition inwhich the endoscopist is challenged to act swift in a tech-
nically demanding retroﬂexed position. Endoscopic managementJournal of Hepatology 20involves single or multiple injection(s) of cyanoacrylate glue into
the varix resulting in the formation of a polymeric plug. Despite its
relative high initial hemostasis rate (87–100%) [1], injection car-
ries distinct risks. First, polymerisation of acrylate beyond the
bleeding site may result in thromboembolic events [1]. Second,
needle obstruction frequently occurs necessitating retrieval. This
means loss of precious time. Third, ulceration of the bleeding site
after injection is commonly seen, and may result in secondary
bleeding [1].
When hemostatic treatment with cyanoacrylate glue fails,
urgent TIPS is not always feasible due to local unavailability,
when the patient condition is too unstable or, as in this case,
when there are clear contraindications such as cardiomyopathy
[6].
HemosprayTM is a novel proprietary hemostatic spray
recently introduced for the management of non-variceal upper
gastrointestinal bleeding. Its safety and efﬁcacy have been
shown in peptic ulcer bleeding [5], as well as in cancer-related
upper GI bleeding [7]. Upon application, this inorganic hemo-
static powder becomes cohesive and adhesive, and forms a sta-
ble mechanical barrier that covers the bleeding site. We report
on the ﬁrst case in literature in which HemosprayTM is success-
fully applied in initially failed endoscopic hemostasis of a vari-
ceal bleeding.
There are few concerns that need to be addressed. Hemo-
sprayTM is applied by a CO2-propelled canister with a positive
outﬂow pressure. Hypothetically, particles may enter the vascu-
lar system and give rise to venous thromboembolisation. How-
ever, the outﬂow pressure at the catheter tip is less than the
known intravariceal venous pressures (often exceeding
15 mmHg) [8] at a distance of 1–2 cm from the mucosa. Also,
data from an ongoing multicentre European initiative on the
use of HemosprayTM for non-variceal upper GI bleeding does
not report incidence of thromboembolism (unpublished data).
Another concern involves the effects of HemosprayTM in coagu-
lation. This is important since most gastric varices occur in cir-
rhotic patients with frequent unbalance of pro- and anti-
coagulatory factors [9]. More studies need to be performed to
elucidate this issue, but preliminary data show only minor
in vitro effects of HemosprayTM on coagulation parameters [10].
In conclusion, Hemospray™ may offer a simple and welcome
alternative in durably controlling bleeding (gastric) varices.
However, we need to await its use in controlled trials to deter-
mine the true added value.
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To the Editor:
We read with great interest a recent article published in this Jour-
nal by Peiseler et al. [1], together with the accompanying editorial
[2], regarding the T regulatory cells (Tregs) in autoimmune
hepatitis (AIH). Peiseler et al. found that CD4+CD25high
CD127lowFOXP3+ Tregs in AIH are ‘‘fully functional and not reduced
in frequency’’. Longhi et al. [3], who had previously published that
Tregs are functionally impaired in AIH, ﬁrst argued against the
methodology used for assessing the Tregs suppressor activity,
since Peiseler et al. employed an ‘‘utterly non-physiological’’ sup-
pressor/effector ratio. Peiseler et al. replied by stating that their
methodology for staining proliferating cells by carboxyﬂuores-
cein succinimidyl ester (CFSE) is more appropriate than
thymidine uptake and speciﬁcally stains the CD4+CD25 effector
T cells.
Another argument was raised regarding the choice of the Tregs
labeling gate that resulted in a lower Tregs frequency compared
with that reported by others [4]. The authors replied [5] by stating
that the frequency of peripheral blood Tregs in adults reported by
Garg et al. is ‘‘not vastly different from the frequencies reported by
us’’. Garg et al. [4] extrapolated that the Tregs number from
CD4+CD25high-labeled cells, considering only the top 1% of
CD25-staining CD4 T cells, as being estimated to be >98%
CD127low. We believe that the comparison of Tregs frequencies
is questionable and age-related, as demonstrated by our data.
Peripheral blood cells from 4 healthy, 4 AIH, and 4 non-alcoholic
steatohepatitis (NASH) children (age range: 10–14 years) were
used to evaluate frequencies of CD4+CD25highCD127lowFOXP3+
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Tregs (Fig. 1A–C). As reported in Fig. 1D, the number of CD25highC-
D127lowFOXP3+ Tregs within the CD4+ population is equal in all
the groups of children. Our data conﬁrms that the number of
CD4+CD25highCD127low ‘True’ Tregs remains unchanged in liver
disease with autoimmune traits, including AIH and NASH as
already reported [1,6]. However, in children, the number of
CD25highCD127lowFOXP3+ Tregs among CD4+ ranges from
between 2.3% and 3.0%. In summary, all of these ﬁndings highlight
the importance of a ‘‘consensus’’ in the standardization of proto-
cols for evaluating the Tregs function in AIH and NASH.
In addition, we would raise a discussion concerning some
aspects related to non-alcoholic steatohepatitis (NASH). Peiseler
et al. determined the intra-hepatic Tregs frequency by immuno-
histochemistry for FOXP3 in 8 NASH patients, in comparison to
AIH [1], and found a higher percentage of FOXP3+ cells in AIH
patients when compared to NASH subjects, both in liver lobules
and in portal tracts. Moreover, they determined that the FOXP3+
cells within the CD3+ population in the liver showed no statistical
differences between AIH and NASH patients. No information
about the diagnosis and severity of NASH was provided by the
authors. Further, the usage of the modiﬁed histological activity
index (mHAI) [7], for quantifying the degree of liver inﬂamma-
tion, is not suitable for NASH patients who are histologically eval-
uated by using the NAFLD Clinical Research Network criteria [8].
As liver-resident inﬂammatory cells are a key component in
NAFLD, particularly in children [9], their role in the severity of
NASH-associated necroinﬂammation and ﬁbrosis requires partic-
ular attention. In fact, we demonstrated that CD3+ cells were sig-
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